EUCODIS Bioscience Launches Beta-Lactamase For Antibiotics and Diagnostics Industries
Vienna, Europe, June 4, 2009 – EUCODIS Bioscience, a company developing enzymes for the chemical, the pharmaceutical, and other industries, announced today that it has successfully launched its first commercial enzyme, a beta-lactamase. The product is manufactured by EUCODIS Bioscience and can be supplied in a GMP-compliant formulation. The Company will market its beta-lactamase to antibiotics manufacturers to improve quality control, to the diagnostics industry, and to research organizations. The Company estimates that its beta-lactamase has a market potential of up to EUR 5 million.
“The launch of a beta-lactamase for the antibiotics industry and other uses opens a new phase in the development of our organization,” said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. “The EUCODIS Bioscience team has demonstrated its capacity to cover the whole value-chain of an integrated enzyme supplier, from enzyme development, to manufacturing, and to marketing. This success adds momentum to our efforts to bring to market further products that we are currently developing. We will continue to provide our development expertise and our technology to industrial partners that want to increase their research and development efficiency.”
Company: EUCODIS Bioscience
contact information:
Contact person: Frank Butschbacher Town: Vienna
Die PresseMitteilung stellt eine Meinungsuerung des Erfassers dar. Der Erfasser hat versichert, dass die eingestellte PresseMitteilung der Wahrheit entspricht, dass sie frei von Rechten Dritter ist und zur Verffentlichung bereitsteht. firmenpresse.de macht sich die Inhalte der PresseMitteilungen nicht zu eigen. Die Haftung fr eventuelle Folgen (z.B. Abmahnungen, Schadenersatzforderungen etc.) bernimmt der Eintrager und nicht firmenpresse.de
